Immune checkpoints: A therapeutic target in triple negative breast cancer

Akhil Chawla; Anne V. Philips; Gheath Alatrash; Elizabeth Mittendorf

doi:10.4161/onci.28325

Immune checkpoints: A therapeutic target in triple negative breast cancer

Akhil Chawla, Anne V. Philips, Gheath Alatrash, Elizabeth Mittendorf

Research output: Contribution to journal › Comment/debate › peer-review

35 Scopus citations

Abstract

Early clinical trials investigating monoclonal antibodies targeting the T-cell inhibitory receptor programmed cell death 1 (PD-1) and its ligand PD-L1 have shown efficacy in melanoma, non-small cell lung cancer and renal cell carcinoma. We recently demonstrated PD-L1 expression in 20% of triple negative breast cancers suggesting that targeting the PD-1/PD-L1 immune checkpoint may be an effective treatment modality in patients with this disease.

Original language	English (US)
Article number	e28325
Journal	OncoImmunology
Volume	3
Issue number	4
DOIs	https://doi.org/10.4161/onci.28325
State	Published - 2014

Keywords

Biomarker
Immunotherapy
PD-L1
PI3K
Triple negative breast cancer

ASJC Scopus subject areas

Immunology and Allergy
Immunology
Oncology

Access to Document

10.4161/onci.28325

Cite this

@article{39c82c15f16f4e8ebd1dd6d0b9e93c7e,

title = "Immune checkpoints: A therapeutic target in triple negative breast cancer",

abstract = "Early clinical trials investigating monoclonal antibodies targeting the T-cell inhibitory receptor programmed cell death 1 (PD-1) and its ligand PD-L1 have shown efficacy in melanoma, non-small cell lung cancer and renal cell carcinoma. We recently demonstrated PD-L1 expression in 20% of triple negative breast cancers suggesting that targeting the PD-1/PD-L1 immune checkpoint may be an effective treatment modality in patients with this disease.",

keywords = "Biomarker, Immunotherapy, PD-L1, PI3K, Triple negative breast cancer",

author = "Akhil Chawla and Philips, {Anne V.} and Gheath Alatrash and Elizabeth Mittendorf",

year = "2014",

doi = "10.4161/onci.28325",

language = "English (US)",

volume = "3",

journal = "OncoImmunology",

issn = "2162-4011",

publisher = "Landes Bioscience",

number = "4",

}

TY - JOUR

T1 - Immune checkpoints

T2 - A therapeutic target in triple negative breast cancer

AU - Chawla, Akhil

AU - Philips, Anne V.

AU - Alatrash, Gheath

AU - Mittendorf, Elizabeth

PY - 2014

Y1 - 2014

N2 - Early clinical trials investigating monoclonal antibodies targeting the T-cell inhibitory receptor programmed cell death 1 (PD-1) and its ligand PD-L1 have shown efficacy in melanoma, non-small cell lung cancer and renal cell carcinoma. We recently demonstrated PD-L1 expression in 20% of triple negative breast cancers suggesting that targeting the PD-1/PD-L1 immune checkpoint may be an effective treatment modality in patients with this disease.

AB - Early clinical trials investigating monoclonal antibodies targeting the T-cell inhibitory receptor programmed cell death 1 (PD-1) and its ligand PD-L1 have shown efficacy in melanoma, non-small cell lung cancer and renal cell carcinoma. We recently demonstrated PD-L1 expression in 20% of triple negative breast cancers suggesting that targeting the PD-1/PD-L1 immune checkpoint may be an effective treatment modality in patients with this disease.

KW - Biomarker

KW - Immunotherapy

KW - PD-L1

KW - PI3K

KW - Triple negative breast cancer

UR - http://www.scopus.com/inward/record.url?scp=84902590227&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902590227&partnerID=8YFLogxK

U2 - 10.4161/onci.28325

DO - 10.4161/onci.28325

M3 - Comment/debate

C2 - 24843833

AN - SCOPUS:84902590227

SN - 2162-4011

VL - 3

JO - OncoImmunology

JF - OncoImmunology

IS - 4

M1 - e28325

ER -

Immune checkpoints: A therapeutic target in triple negative breast cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this